Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus NABUMETONE.
Head-to-head clinical analysis: EC NAPROSYN versus NABUMETONE.
EC-NAPROSYN vs NABUMETONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that acts as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA), is responsible for its therapeutic effects.
500-1000 mg orally twice daily; maximum 1500 mg/day.
1000 mg orally once daily with food; may increase to 1500-2000 mg/day in divided doses if needed.
None Documented
None Documented
Clinical Note
moderateNabumetone + Gatifloxacin
"Nabumetone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNabumetone + Rosoxacin
"Nabumetone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNabumetone + Levofloxacin
"Nabumetone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNabumetone + Trovafloxacin
"Nabumetone may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 22-30 hours in healthy adults, allowing once-daily dosing. Steady state is achieved after 3-5 days.
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Approximately 80% of a dose is excreted in urine as metabolites (primarily 6-methoxy-2-naphthylacetic acid and its glucuronide conjugates), with about 10% excreted in feces. Biliary excretion is minimal.
Category C
Category D/X
NSAID
NSAID